Cargando…

Bioactive components of Chinese herbal medicine enhance endogenous neurogenesis in animal models of ischemic stroke: A systematic analysis

BACKGROUND: Chinese herbal medicine (CHM) has been used to treat stroke for thousands of years. The objective of the study is to assess the current evidence for bioactive components of CHM as neurogenesis agent in animal models of ischemic stroke. METHODS: We searched PubMed, China National Knowledg...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ji-Huang, Chen, Zi-Xian, Zhang, Xiao-Guang, Li, Yan, Yang, Wen-Ting, Zheng, Xia-Wei, Chen, Shuang, Lu, Lin, Gu, Yong, Zheng, Guo-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059049/
https://www.ncbi.nlm.nih.gov/pubmed/27749547
http://dx.doi.org/10.1097/MD.0000000000004904
_version_ 1782459366224429056
author Li, Ji-Huang
Chen, Zi-Xian
Zhang, Xiao-Guang
Li, Yan
Yang, Wen-Ting
Zheng, Xia-Wei
Chen, Shuang
Lu, Lin
Gu, Yong
Zheng, Guo-Qing
author_facet Li, Ji-Huang
Chen, Zi-Xian
Zhang, Xiao-Guang
Li, Yan
Yang, Wen-Ting
Zheng, Xia-Wei
Chen, Shuang
Lu, Lin
Gu, Yong
Zheng, Guo-Qing
author_sort Li, Ji-Huang
collection PubMed
description BACKGROUND: Chinese herbal medicine (CHM) has been used to treat stroke for thousands of years. The objective of the study is to assess the current evidence for bioactive components of CHM as neurogenesis agent in animal models of ischemic stroke. METHODS: We searched PubMed, China National Knowledge Infrastructure, WanFang Database, and VIP Database for Chinese Technical Periodicals published from the inception up to November 2015. The primary measured outcome was one of neurogenesis biomarker, including Bromodeoxyuridine (BrdU), Nestin, doublecortin (DCX), polysialylated form of the neural cell adhesion molecule (PSA-NCAM), neuronal nuclear antigen (NeuN), and glial fibrillary acidic protein (GFAP). RESULTS: Thirty eligible studies were identified. The score of quality assessment ranged from 2 of 10 to 7 of 10. Compared with controls, 10 studies conducting neurobehavioral evaluation showed significant effects on bioactive components of CHM for improving neurological deficits score after ischemic insults (P < 0.01 or P < 0.05); 6 studies in Morris water-maze test showed bioactive components of CHM significantly decreased escape latency and increased residence time (P < 0.05); 5 studies demonstrated that bioactive components of CHM significantly reduced infarct volume after ischemic stroke (P < 0.05); 25 of 26 studies showed that bioactive components of CHM significantly increased the expression of BrdU and/or Nestin markers in rats/mice brain after ischemic injury (P < 0.05, or P < 0.01); 4 of 5 studies for promoting the expression of PSA-NCAM or DCX biomarker (P < 0.05); 5 studies for improving the expression of NeuN biomarker (P < 0.05); 6 of 7 studies for promoting the expression of GFAP biomarker in brain after ischemic stroke (P < 0.05). CONCLUSION: The findings suggest that bioactive components of CHM may improve neurological function, reduce infarct volume, and promote endogenous neurogenesis, including proliferation, migration, and differentiation of neural stem cells after ischemic stroke. However, evidences are supported but limited because only a few studies were available for each descriptive analysis. Further rigor study is still needed.
format Online
Article
Text
id pubmed-5059049
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-50590492016-11-01 Bioactive components of Chinese herbal medicine enhance endogenous neurogenesis in animal models of ischemic stroke: A systematic analysis Li, Ji-Huang Chen, Zi-Xian Zhang, Xiao-Guang Li, Yan Yang, Wen-Ting Zheng, Xia-Wei Chen, Shuang Lu, Lin Gu, Yong Zheng, Guo-Qing Medicine (Baltimore) 3800 BACKGROUND: Chinese herbal medicine (CHM) has been used to treat stroke for thousands of years. The objective of the study is to assess the current evidence for bioactive components of CHM as neurogenesis agent in animal models of ischemic stroke. METHODS: We searched PubMed, China National Knowledge Infrastructure, WanFang Database, and VIP Database for Chinese Technical Periodicals published from the inception up to November 2015. The primary measured outcome was one of neurogenesis biomarker, including Bromodeoxyuridine (BrdU), Nestin, doublecortin (DCX), polysialylated form of the neural cell adhesion molecule (PSA-NCAM), neuronal nuclear antigen (NeuN), and glial fibrillary acidic protein (GFAP). RESULTS: Thirty eligible studies were identified. The score of quality assessment ranged from 2 of 10 to 7 of 10. Compared with controls, 10 studies conducting neurobehavioral evaluation showed significant effects on bioactive components of CHM for improving neurological deficits score after ischemic insults (P < 0.01 or P < 0.05); 6 studies in Morris water-maze test showed bioactive components of CHM significantly decreased escape latency and increased residence time (P < 0.05); 5 studies demonstrated that bioactive components of CHM significantly reduced infarct volume after ischemic stroke (P < 0.05); 25 of 26 studies showed that bioactive components of CHM significantly increased the expression of BrdU and/or Nestin markers in rats/mice brain after ischemic injury (P < 0.05, or P < 0.01); 4 of 5 studies for promoting the expression of PSA-NCAM or DCX biomarker (P < 0.05); 5 studies for improving the expression of NeuN biomarker (P < 0.05); 6 of 7 studies for promoting the expression of GFAP biomarker in brain after ischemic stroke (P < 0.05). CONCLUSION: The findings suggest that bioactive components of CHM may improve neurological function, reduce infarct volume, and promote endogenous neurogenesis, including proliferation, migration, and differentiation of neural stem cells after ischemic stroke. However, evidences are supported but limited because only a few studies were available for each descriptive analysis. Further rigor study is still needed. Wolters Kluwer Health 2016-10-07 /pmc/articles/PMC5059049/ /pubmed/27749547 http://dx.doi.org/10.1097/MD.0000000000004904 Text en Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author. http://creativecommons.org/licenses/by-nd/4.0
spellingShingle 3800
Li, Ji-Huang
Chen, Zi-Xian
Zhang, Xiao-Guang
Li, Yan
Yang, Wen-Ting
Zheng, Xia-Wei
Chen, Shuang
Lu, Lin
Gu, Yong
Zheng, Guo-Qing
Bioactive components of Chinese herbal medicine enhance endogenous neurogenesis in animal models of ischemic stroke: A systematic analysis
title Bioactive components of Chinese herbal medicine enhance endogenous neurogenesis in animal models of ischemic stroke: A systematic analysis
title_full Bioactive components of Chinese herbal medicine enhance endogenous neurogenesis in animal models of ischemic stroke: A systematic analysis
title_fullStr Bioactive components of Chinese herbal medicine enhance endogenous neurogenesis in animal models of ischemic stroke: A systematic analysis
title_full_unstemmed Bioactive components of Chinese herbal medicine enhance endogenous neurogenesis in animal models of ischemic stroke: A systematic analysis
title_short Bioactive components of Chinese herbal medicine enhance endogenous neurogenesis in animal models of ischemic stroke: A systematic analysis
title_sort bioactive components of chinese herbal medicine enhance endogenous neurogenesis in animal models of ischemic stroke: a systematic analysis
topic 3800
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059049/
https://www.ncbi.nlm.nih.gov/pubmed/27749547
http://dx.doi.org/10.1097/MD.0000000000004904
work_keys_str_mv AT lijihuang bioactivecomponentsofchineseherbalmedicineenhanceendogenousneurogenesisinanimalmodelsofischemicstrokeasystematicanalysis
AT chenzixian bioactivecomponentsofchineseherbalmedicineenhanceendogenousneurogenesisinanimalmodelsofischemicstrokeasystematicanalysis
AT zhangxiaoguang bioactivecomponentsofchineseherbalmedicineenhanceendogenousneurogenesisinanimalmodelsofischemicstrokeasystematicanalysis
AT liyan bioactivecomponentsofchineseherbalmedicineenhanceendogenousneurogenesisinanimalmodelsofischemicstrokeasystematicanalysis
AT yangwenting bioactivecomponentsofchineseherbalmedicineenhanceendogenousneurogenesisinanimalmodelsofischemicstrokeasystematicanalysis
AT zhengxiawei bioactivecomponentsofchineseherbalmedicineenhanceendogenousneurogenesisinanimalmodelsofischemicstrokeasystematicanalysis
AT chenshuang bioactivecomponentsofchineseherbalmedicineenhanceendogenousneurogenesisinanimalmodelsofischemicstrokeasystematicanalysis
AT lulin bioactivecomponentsofchineseherbalmedicineenhanceendogenousneurogenesisinanimalmodelsofischemicstrokeasystematicanalysis
AT guyong bioactivecomponentsofchineseherbalmedicineenhanceendogenousneurogenesisinanimalmodelsofischemicstrokeasystematicanalysis
AT zhengguoqing bioactivecomponentsofchineseherbalmedicineenhanceendogenousneurogenesisinanimalmodelsofischemicstrokeasystematicanalysis